Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a report issued on Tuesday morning, Marketbeat.com reports.
A number of other equities analysts have also recently issued reports on the stock. BMO Capital Markets reissued an outperform rating on shares of AstraZeneca in a research report on Monday, February 12th. Berenberg Bank boosted their price target on shares of AstraZeneca from £120 ($152.52) to £130 ($165.23) and gave the stock a buy rating in a report on Friday, May 3rd. Jefferies Financial Group reissued a hold rating and issued a £110 ($139.81) target price on shares of AstraZeneca in a research report on Friday, February 16th. JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a research note on Thursday, April 4th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a hold rating and set a £105 ($133.45) price objective on shares of AstraZeneca in a research note on Tuesday, April 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of £118 ($149.97).
Check Out Our Latest Research Report on AstraZeneca
AstraZeneca Price Performance
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
- Five stocks we like better than AstraZeneca
- Short Selling: How to Short a Stock
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- 5 discounted opportunities for dividend growth investors
- These 2 Retail Traders Favorites are Nearing Major Breakouts
- What is the S&P/TSX Index?
- Snowflake is Melting… Up, With a Double-Digit Upside Potential
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.